Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. director and scientific advisory board chair Xiaodong Wang reported new equity awards. He received 99,892 Ordinary Shares at a price of $0.00 per share, bringing his direct holdings to 4,682,493 Ordinary Shares after the award.
Wang was also granted a share option for 193,492 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. The footnotes state that these option shares vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder in 36 monthly installments, subject to continued service. Additional Ordinary Shares are held indirectly by a family trust, Wang Investment LLC, and Wang’s spouse, for which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.
BRANDICOURT OLIVIER reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Olivier Brandicourt received a grant of 18,980 Ordinary Shares in the form of restricted share units on June 11, 2026 at no cash cost, as director compensation. These restricted share units vest in full on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Brandicourt directly holds 46,306 Ordinary Shares.
HOOPER ANTHONY C reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Anthony C. Hooper received an equity grant of 18,980 Ordinary Shares in the form of restricted share units at no cash cost on 2026-06-11. These restricted share units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Hooper holds 83,720 Ordinary Shares directly.
Mooney Elizabeth Fisher reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney received an equity grant representing 18,980 Ordinary Shares on a Form 4 filing. These shares underlie restricted share units granted at a price of $0.00 per share as a compensation award rather than a market purchase.
The restricted share units will become fully vested on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting stops if she resigns from the board or otherwise ceases to serve as a director, unless accelerated under the company’s Independent Non-Executive Director Compensation Policy.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Margaret Dugan received an equity award of 18,980 Ordinary Shares on June 11, 2026, reported at a price of $0.0000 per share. These represent securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Dugan directly holds 73,164 Ordinary Shares.
Sawyers Charles Lazelle reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Charles Lazelle Sawyers reported a grant of 18,980 Ordinary Shares as a share-based award. The award represents restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting triggers under the company’s Independent Non-Executive Director Compensation Policy. Following the award, he holds 18,984 Ordinary Shares directly. A separate entry shows 1,946 American Depositary Shares held directly, and each American Depositary Share represents 13 Ordinary Shares.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Shalini Sharp reported a compensation-related equity award. She received 18,980 Ordinary Shares for no cash payment, described as securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and possible accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. After this award, she directly holds 38,116 Ordinary Shares. A separate line shows direct ownership of 9 American Depositary Shares, with each American Depositary Share representing 13 Ordinary Shares.
Riva Alessandro reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Alessandro Riva received a grant of 18,980 ordinary shares in the form of restricted share units at no purchase price. These units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to his continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Riva directly holds 73,164 ordinary shares.
BeOne Medicines Ltd. director Charles Lazelle Sawyers filed an initial Form 3 reporting his ownership in the company. He directly holds 1,946 American Depositary Shares and 4 ordinary shares as of June 11, 2026. Each American Depositary Share represents 13 ordinary shares.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing summary in this excerpt shows no reported purchases, sales, exercises, gifts, restructurings, or other equity transactions and no listed holdings.